目的：通过经外周静脉穿刺中心静脉置管（PICC）或锁骨下静脉置管与前臂静脉留置针在血液病患者并发深部真菌感染时应用两性霉素B中的比较，探讨如何减少患者静脉炎及并发症发生率和再次静脉穿刺的发生率，从而提高患者生活质量。方法：80例血液病患者分为两组，40例PICC置管或锁骨下静脉置管组为A组，40例前臂静脉留置针为B组，记录静脉炎、疼痛发生情况、留置时间。结果：A组留置时间30～68天，B组留置时间1～5天；A组静脉炎率5%，B组静脉炎率45%；A组疼痛率5%，B组疼痛率35%；结论：在血液病患者并发深部真菌感染时应用两性霉素B治疗中，选用PICC置管或锁骨下静脉置管效果明显优于前臂静脉留置针，值得临床推广。
【摘要】 目的 研究以万珂为主化学疗法方案提高多发性骨髓瘤初发患者自体外周血造血干细胞采集的作用。 方法 回顾性分析2006年1月-2010年11月4例初发多发性骨髓瘤患者在万珂治疗后自体外周血造血干细胞采集的临床资料。疗效判定依据国际骨髓瘤工作组2006年疗效判断标准。 结果 经过万珂为主化学疗法方案治疗3~6个疗程（平均4个疗程）后，3例获得CR及以上疗效，均顺利实施了外周血造血干细胞采集；3例采集次数仅1次，1例为2次；平均获得CD34+细胞8.43×106/kg，完全达到采集要求。 结论 万珂为主化学疗法方案起效快、疗效好，可以提高初发多发性骨髓瘤患者的干细胞采集率。【Abstract】 Objective To explore the improvement of autologous stem cells collection in patients with newly-diagnosed multiple myeloma after Velcade-based chemotherapy. Methods The clinical data of four patients with multiple myeloma who underwent Velcade-based chemotherapy between January 2006 and November 2010 were retrospectively analyzed. The therapeutic effect was observed. Results After 3-6 courses (mean 4 courses) of Velcade-based chemotherapy, 3 patients obtained complete remission (CR) and above response, and the sufficient peripheral blood hematopoietic stem cells were collected successfully. The peripheral blood hematopoietic stem cells were collected once in three patients and twice in one patient. Sufficient number of hematopoietic stem cells (mean CD34 positive-cell 8.43×106/kg) were collected which fully met the collection requirements. Conclusion Velcade-based chemotherapy has advantages of fast action and good therapeutic effect, which can improve the collection of autologous stem cells in patients with newly-diagnosed multiple myeloma.